Dr. Craig Campbell is the Acting Chair of Pediatrics (Research), the Head of the Division of Pediatric Neurology and the medical director of the multidisciplinary neuromuscular clinic based at Thames Valley Children’s Centre and the Pediatric Neurophysiology Laboratory at Children’s Hospital London Health Sciences Centre. He is a Full Professor in Pediatrics, Clinical Neurological Sciences and Epidemiology at Western University and a Scientist at the Children’s Health Research Institute. His training in pediatrics, neurology and epidemiology was completed at the University of Ottawa.
Dr. Campbell is collaboratively involved in many academic and industry initiated clinical trial activities in pediatric neuromuscular disease. He is a member of the Muscle Study Group and the World Muscle Society, and co-chair of the TREAT-NMD Registry Oversight Committee and Task Force. Dr. Campbell has been awarded the George Karpati Award Researcher of the Year in 2011 and 2015 by Muscular Dystrophy Canada.
As part of NMD4C Dr. Campbell is implementing innovations for the Canadian Neuromuscular Disease Registry that facilitate data sharing and patient engagement. He will also be developing a research curriculum and clinical trial network.
Trelford, CB, Ng, E, Campbell, CI, Di Guglielmo, GM. p62/Sequestosome 1 regulates transforming growth factor beta signaling and epithelial to mesenchymal transition in A549 cells. Cell Signal. 2021.85 110040 PMID:34000385
McInnis, C, Garcia, MJS, Widjaja, E, Frndova, H, Huyse, JV, Guerguerian, AM et al.. Magnetic Resonance Imaging Findings Are Associated with Long-Term Global Neurological Function or Death after Traumatic Brain Injury in Critically Ill Children. J Neurotrauma. 2021. PMID:33787327
Almobarak, S, Hu, J, Langdon, KD, Ang, LC, Campbell, C. α-tropomyosin gene (TPM3) mutation in an infant with nemaline myopathy. Clin Case Rep. 2021.9 (3)1672-1676 PMID:33768912
Rudnicki, SA, Andrews, JA, Duong, T, Cockroft, BM, Malik, FI, Meng, L et al.. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021. PMID:33624184
Wagner, KR, Abdel-Hamid, HZ, Mah, JK, Campbell, C, Guglieri, M, Muntoni, F et al.. Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]. Neuromuscul Disord. 2021.31 (2)167-168 PMID:33451933See more on PubMed